Presidio Partners 2007, L.P.
CIK 1405712 · last filed 2015-12-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ASPX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
San Francisco, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | 10%+ Owner | 2,539,706 | $3.17 | $8.05M | $0 | 2 | 2015-12-17 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | 10%+ Owner | 3,041,610 | — | — | -$50.00M | 19 | 2015-02-17 |
Recent Filings · Page 2 of 3
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-09-09 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −17,400 | -$393.1K | EDGAR |
| 2014-09-09 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −3,400 | -$69.9K | EDGAR |
| 2014-09-09 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −45,400 | -$1.05M | EDGAR |
| 2014-09-09 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −10,800 | -$224.7K | EDGAR |
| 2014-09-09 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −12,600 | -$269.0K | EDGAR |
| 2014-09-08 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −51,200 | -$1.22M | EDGAR |
| 2014-09-08 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Exer (X) | +94,056 | $364.8K | EDGAR |
| 2014-09-04 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −45,400 | -$1.05M | EDGAR |
| 2014-09-03 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −17,400 | -$393.1K | EDGAR |
| 2014-08-29 | Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Sell (S) | −59,200 | -$1.30M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.